Clinical Trials

28 enrolled

Breast Neoplasms

NCT05143970 2026-03-20

CHANCES

BreastGastrointestinalGynecologicThoracic

27 enrolled

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04253561 2026-03-16

IPATHER

17 enrolled

Breast Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

200 enrolled

Breast Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

20 enrolled

Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT03448042 2026-02-27

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

123 enrolled

Other solid neoplasm

Solid Tumors

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT05553522 2025-12-31

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

1 enrolled

CNS

Brain Neoplasms

NCT06328738 2025-11-19

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

275 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03716180 2025-09-22

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

100 enrolled

Breast Neoplasms

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

2 enrolled

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

200 enrolled

Breast Neoplasms

NCT04487236 2025-08-11

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

61 enrolled

CNS

Brain Neoplasms

NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

174 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT06886659 2025-07-22

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

80 enrolled

Breast Diseases, Breast Neoplasms

NCT03767335 2025-06-26

B-PRECISE-01

62 enrolled 18 charts

Breast Neoplasms

NCT00393783 2025-06-05

Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

13 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

BreastDermatologicLymphoid

17 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

13 enrolled 11 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

18 enrolled 14 charts

Breast Neoplasms

NCT01921335 2024-11-06

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

41 enrolled

Breast Neoplasms

NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Phase 1 Suspended

24 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00963547 2024-06-04

MK-2206-015

33 enrolled 13 charts

Breast Neoplasms

NCT06162559 2024-01-11

TRAIN-4

30 enrolled

Breast Neoplasms

NCT01300962 2023-12-04

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

47 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04367090 2023-09-18

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

97 enrolled

Breast Neoplasms

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

15 enrolled

Breast Neoplasms

NCT00251433 2023-03-31

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

53 enrolled

Breast Neoplasms

NCT05765357 2023-03-13

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

89 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT01969643 2023-03-07

A Safety Study of SGN-LIV1A in Breast Cancer Patients

290 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02627274 2022-11-22

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

134 enrolled

BreastHead & Neck

Breast Neoplasms, Head and Neck Neoplasms

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

65 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03364348 2022-10-19

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

18 enrolled 17 charts

Breast Neoplasms

NCT02569489 2022-07-18

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03916094 2022-05-05

Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2

11 enrolled

Other solid neoplasm

Solid Tumor

NCT05301530 2022-03-29

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

50 enrolled

Breast Cancer Metastatic

NCT02562378 2022-02-23

THELMA

15 enrolled 39 charts

Breast Neoplasms

NCT03319459 2021-11-22

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors